ABSTRACT
Background Thrombocytosis is associated with poor lung cancer prognosis and has recently been identified as having a high predictive value in lung cancer detection. Lung cancer has multiple histological and genetic subtypes and it is not known whether platelet levels differ across subtypes.
Methods PubMed and Embase were systematically searched for studies that reported pre-treatment platelet count, as either averages or proportion of patients with thrombocytosis, by histological subtype of lung cancer. Suitable studies were synthesised in meta-analyses; subgroup analyses examined for differences across subtypes.
Results The prevalence of pre-treatment thrombocytosis across all lung cancer patients was 27% (95% CI: 17 to 37%). By subtype, this was 22% (95% CI: 7 to 41%) for adenocarcinoma (ADC), 28% (95% CI: 15 to 43%) for squamous cell carcinoma (SCC), 36% (95% CI: 13 to 62%) for large cell carcinoma, and 30% (95% CI: 8 to 58%) for small cell lung cancer (SCLC). The pooled mean platelet count for lung cancer patients was 289×109 /L (95% CI: 268 to 311). By subtype, this was 282×109 /L (95% CI: 259 to 306) for ADC, 297×109 /L (95% CI: 238 to 356) for SCC, 290×109 /L (95% CI: 176 to 404) for LCC, and 293×109 /L (95% CI: 244 to 342) for SCLC. There was no difference in thrombocytosis prevalence (p=0.76) or mean platelet count (p=0.96) across the subtypes.
Conclusion We report no evidence of differences in platelet levels across the major subtypes of lung cancer. A high platelet level is likely to be generic across all lung cancer subtypes.
What is the key question?Which (if any) subtype(s) of lung cancer are more associated with thrombocytosis?
What is the bottom line?This can facilitate lung cancer diagnostics and provide insights into the biological mechanism between lung cancer and thrombocytosis.
Why read on?This is the first systematic review to compare platelet count across different subtypes of lung cancer, combining data from 9,891 patients across 38 studies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020162965
Funding Statement
This work was supported by grant MR/N0137941/1 for the GW4 BIOMED DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI held by MB. This work was also supported by the CanTest Collaborative (funded by Cancer Research UK C8640/A23385) of which WH is a co-director, and from which SERB receives salary support. OU was supported by the National Institute for Health Research (NIHR) Applied Research Collaboration SouthWest Peninsula (PenARC). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care. The funding sources had no role in the study design, data collection, data analysis, data interpretation, writing of the report or in the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Systematic Review. IRB/ethics committee exempt.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available by contacting Melissa Barlow (corresponding author) ms748@exeter.ac.uk
